TPTX Tshuag Ob npaug ntawm Bristol Myers '$ 4.1 Billion Tag Nrho Nyiaj Txiag

Turning Point Therapeutics (TPTX) snagged $4.1 nphom kev muab los ntawm Bristol Myers Squibb (BMY) Hnub Friday, thiab TPTX Tshuag ntau dua ob npaug.

X

Qhov kev pom zoo ntxiv repotrectinib rau Bristol Myers ' wheelhouse. Repotrectinib yog ib qho kev kho mob rau cov neeg mob qog nqaij hlav cancer nrog ib qho kev hloov ntawm caj ces. Nws cia siab tias yuav tso tawm xyoo tom ntej.

Wedbush tus kws tshuaj ntsuam David Nierengarten hais tias qhov kev pom zoo tuaj yeem yog qhov zoo rau qhov chaw mob qog noj ntshav thiab rau cov me me / nruab nrab-cap biotechs zoo li Daim Ntawv Qhia Tshuaj (BPMC), Cogent Biosciences (COGT), Kinnate Biopharma (KNTE) thiab Theseus Pharmaceuticals (THRX).

"Txawm hais tias nws tsis paub meej yog Bristol Myers qhov tau txais ntawm Turning Point yog ib qho kev pom zoo ntawm ntau qhov kev cog lus los ntawm cov phiaj xwm oncology, peb ntseeg tias nws tuaj yeem kos qhov xaus ntawm kev lag luam biotech dais tsis ntev los no," nws hais.

Hauv nruab nrab kev lag luam rau hnub no lub khw lag luam, TPTX Tshuag rocketed 116.8% siab dua, ze 74.10. Bristol Myers Tshuag, ntawm qhov tod tes, poob ib feem nyob ze 74.90.

TPTX Stock Grabs Major Premium

Raws li cov lus cog tseg, Bristol Myers yuav them 76 ib feem ntawm Turning Point Tshuag - 122% tus nqi them rau hnub Thursday tus nqi kaw. Qhov kev pom zoo yog kev muab nyiaj ntsuab tag nrho thiab ob pawg thawj coj ntawm cov thawj coj tau kos npe tawm ntawm nws. Bristol Myers npaj yuav qhwv qhov kev sib pauv hauv peb lub hlis twg.

Bristol Myers cia siab tias qhov kev hloov pauv yuav muaj txog li 8-xees cuam tshuam rau kev hloov kho cov nyiaj tau los hauv 2022. Tab sis lub tuam txhab hais tias qhov kev cog lus yuav muaj txiaj ntsig zoo rau cov txiaj ntsig pib xyoo 2025. Bristol Myers cia siab tias yuav tau txais nyiaj txiag kev lag luam nrog nyiaj ntsuab ntawm tes.

Bristol Myers Tus Thawj Coj Tus Thawj Coj Giovanni Caforio tau hais tias "Kev nrhiav tau ntawm Turning Point Therapeutics txuas ntxiv nthuav dav peb cov thawj coj ntawm oncology franchise los ntawm kev ntxiv qhov zoo tshaj plaws-hauv-chav kawm, theem kawg ntawm kev ua haujlwm ntawm oncology," Bristol Myers Chief Executive Giovanni Caforio tau hais hauv nqe lus sau.

Cov xov xwm xa TPTX Tshuag mus rau nws qhov siab tshaj plaws txij thaum Lub Kaum Hli. Nws kuj tau thawb cov khoom lag luam zoo tshaj lawv 200-hnub mus nruab nrab thawj zaug txij li lub Peb Hlis 2021, raws li MarketSmith.com.

Ua raws li Allison Gatlin ntawm Twitter ntawm @IBD_AGatlin.

KOJ UA LI CAS:

Lub Bullish Move Veeva Systems tsuas yog ua tom qab nws Daim Ntawv Qhia Peb Hlis

Regeneron Pharmaceuticals Dives Ntawm $ 1.1 Billion Deal Rau Rival Merck Hauv Cancer

IBD Digital: Txhim Kho IBD Daim Ntawv Teev Khoom Tseem Ceeb, Cov Cuab Yeej Thiab Cuam Tshuam Hnub no

Nrhiav Kom Tom Ntej Kua Los Yog Amazon? Pib Nrog Cov S&P 500-Npav Npe

Pom Qhov Kev Lag Luam Zoo Tshaj Plaws Sij Hawm Zoo Nrog IBD Cov Thawj Coj Ua Haujlwm Ntev